Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. On February 10, 2025, Omega Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Metrics to compare | OMGAQ | Sector Sector - Average of metrics from a broad group of related Financial sector companies | Relationship RelationshipOMGAQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −1.7x | −0.5x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.0x | 0.8x | 2.6x | |
Price / LTM Sales | 0.0x | 41.5x | 3.3x | |
Upside (Analyst Target) | - | 246.8% | 43.5% | |
Fair Value Upside | Unlock | 34.8% | 6.8% | Unlock |